Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy

C. C. Chi, G. Kirtschig, W. Aberer, J. P. Gabbud, J. Lipozenčić, S. Kárpáti, U. F. Haustein, F. Wojnarowska, T. Zuberbier

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Topical corticosteroids may be needed for treating skin conditions in pregnancy. Nevertheless, only limited data on the fetal effects of topical corticosteroids are available. Objective: To update an evidence-based guideline on the safe use of topical corticosteroids in pregnancy. Methods: A guideline subcommittee of the European Dermatology Forum updated the guideline by adding and appraising new evidence. Results: The current best evidence from 14 observational studies with 1 601 515 study subjects found no significant associations between maternal use of topical corticosteroids of any potency and some adverse pregnancy outcomes including mode of delivery, birth defect, preterm delivery and fetal death. However, maternal use of potent/very potent topical corticosteroids, especially in large amounts, is associated with an increase in the risk of low birthweight. Conclusion: Mild/moderate topical corticosteroids should be preferred to potent/very potent ones in pregnancy. The well-known topical side-effects of corticosteroids on the mother's side need to be considered as well.

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Dermatology
Adrenal Cortex Hormones
Guidelines
Pregnancy
Mothers
Fetal Death
Pregnancy Outcome
Observational Studies
Skin

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. / Chi, C. C.; Kirtschig, G.; Aberer, W.; Gabbud, J. P.; Lipozenčić, J.; Kárpáti, S.; Haustein, U. F.; Wojnarowska, F.; Zuberbier, T.

In: Journal of the European Academy of Dermatology and Venereology, 2017.

Research output: Contribution to journalArticle

Chi, C. C. ; Kirtschig, G. ; Aberer, W. ; Gabbud, J. P. ; Lipozenčić, J. ; Kárpáti, S. ; Haustein, U. F. ; Wojnarowska, F. ; Zuberbier, T. / Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. In: Journal of the European Academy of Dermatology and Venereology. 2017.
@article{23e07196db234939a5331e38470c3131,
title = "Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy",
abstract = "Background: Topical corticosteroids may be needed for treating skin conditions in pregnancy. Nevertheless, only limited data on the fetal effects of topical corticosteroids are available. Objective: To update an evidence-based guideline on the safe use of topical corticosteroids in pregnancy. Methods: A guideline subcommittee of the European Dermatology Forum updated the guideline by adding and appraising new evidence. Results: The current best evidence from 14 observational studies with 1 601 515 study subjects found no significant associations between maternal use of topical corticosteroids of any potency and some adverse pregnancy outcomes including mode of delivery, birth defect, preterm delivery and fetal death. However, maternal use of potent/very potent topical corticosteroids, especially in large amounts, is associated with an increase in the risk of low birthweight. Conclusion: Mild/moderate topical corticosteroids should be preferred to potent/very potent ones in pregnancy. The well-known topical side-effects of corticosteroids on the mother's side need to be considered as well.",
author = "Chi, {C. C.} and G. Kirtschig and W. Aberer and Gabbud, {J. P.} and J. Lipozenčić and S. K{\'a}rp{\'a}ti and Haustein, {U. F.} and F. Wojnarowska and T. Zuberbier",
year = "2017",
doi = "10.1111/jdv.14101",
language = "English",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy

AU - Chi, C. C.

AU - Kirtschig, G.

AU - Aberer, W.

AU - Gabbud, J. P.

AU - Lipozenčić, J.

AU - Kárpáti, S.

AU - Haustein, U. F.

AU - Wojnarowska, F.

AU - Zuberbier, T.

PY - 2017

Y1 - 2017

N2 - Background: Topical corticosteroids may be needed for treating skin conditions in pregnancy. Nevertheless, only limited data on the fetal effects of topical corticosteroids are available. Objective: To update an evidence-based guideline on the safe use of topical corticosteroids in pregnancy. Methods: A guideline subcommittee of the European Dermatology Forum updated the guideline by adding and appraising new evidence. Results: The current best evidence from 14 observational studies with 1 601 515 study subjects found no significant associations between maternal use of topical corticosteroids of any potency and some adverse pregnancy outcomes including mode of delivery, birth defect, preterm delivery and fetal death. However, maternal use of potent/very potent topical corticosteroids, especially in large amounts, is associated with an increase in the risk of low birthweight. Conclusion: Mild/moderate topical corticosteroids should be preferred to potent/very potent ones in pregnancy. The well-known topical side-effects of corticosteroids on the mother's side need to be considered as well.

AB - Background: Topical corticosteroids may be needed for treating skin conditions in pregnancy. Nevertheless, only limited data on the fetal effects of topical corticosteroids are available. Objective: To update an evidence-based guideline on the safe use of topical corticosteroids in pregnancy. Methods: A guideline subcommittee of the European Dermatology Forum updated the guideline by adding and appraising new evidence. Results: The current best evidence from 14 observational studies with 1 601 515 study subjects found no significant associations between maternal use of topical corticosteroids of any potency and some adverse pregnancy outcomes including mode of delivery, birth defect, preterm delivery and fetal death. However, maternal use of potent/very potent topical corticosteroids, especially in large amounts, is associated with an increase in the risk of low birthweight. Conclusion: Mild/moderate topical corticosteroids should be preferred to potent/very potent ones in pregnancy. The well-known topical side-effects of corticosteroids on the mother's side need to be considered as well.

UR - http://www.scopus.com/inward/record.url?scp=85013632903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013632903&partnerID=8YFLogxK

U2 - 10.1111/jdv.14101

DO - 10.1111/jdv.14101

M3 - Article

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

ER -